Clinical trial
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
NCT00003827 · ALZA, Industry · Unknown status
Key facts
| NCT number | NCT00003827 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome |
| Official title | Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study |
| Lead sponsor | ALZA, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, cytarabine, topotecan hydrochloride |
| Enrollment | 25 |
| Start date | Jan 1, 1999 |
| First posted | Sep 25, 2003 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: